Callan Capital LLC Purchases New Position in Takeda Pharmaceutical Co. (NYSE:TAK)

Callan Capital LLC bought a new stake in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 49,425 shares of the company's stock, valued at approximately $735,000.

Several other institutional investors have also recently added to or reduced their stakes in TAK. Soleus Capital Management L.P. increased its holdings in Takeda Pharmaceutical by 136.0% in the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock valued at $15,623,000 after purchasing an additional 680,000 shares during the last quarter. Toronto Dominion Bank acquired a new position in shares of Takeda Pharmaceutical in the fourth quarter worth $6,760,000. BNP Paribas Financial Markets grew its stake in shares of Takeda Pharmaceutical by 15,449.0% in the fourth quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock worth $6,629,000 after acquiring an additional 497,457 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Takeda Pharmaceutical in the fourth quarter worth $5,915,000. Finally, Summit Global Investments grew its stake in shares of Takeda Pharmaceutical by 75.5% in the fourth quarter. Summit Global Investments now owns 729,200 shares of the company's stock worth $9,655,000 after acquiring an additional 313,642 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Down 2.0%

Shares of TAK stock traded down $0.30 on Thursday, reaching $14.83. 2,083,421 shares of the stock were exchanged, compared to its average volume of 1,992,972. The company has a current ratio of 1.01, a quick ratio of 0.52 and a debt-to-equity ratio of 0.57. The business's 50 day moving average price is $14.86 and its 200 day moving average price is $14.36. The company has a market capitalization of $47.20 billion, a price-to-earnings ratio of 67.39 and a beta of 0.23. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The firm had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. As a group, sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.